Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms

CompletedOBSERVATIONAL
Enrollment

442

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

December 31, 2020

Conditions
Myeloproliferative Neoplasm
Interventions
DRUG

DOACs

Direct Oral Anticoagulants

Trial Locations (18)

10029

Mount Sinai New York, New York

10126

A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia, Torino

20900

ASST MONZA Ospedale San Gerardo Clinica Ematologica, Monza

24127

ASST- Papa Giovanni XXIII - S.I.M.T., Bergamo

27100

Fondazione IRCCS Policlinico San Matteo S.C Ematologia, Pavia

36100

Ospedale San Bortolo di Vicenza - U.O.C di Ematologia, Vicenza

37134

Divisione Ematologia, Ospedale Borgo Roma, Verona

80131

Azienda Ospedaliera Universitaria Federico II di Napoli Divisione di Ematologia e Trapianti del Midollo, Napoli

Unknown

Princess Margaret Cancer Centre Toronto, Toronto

Centre Hospitalier Universitaire de Brest, Brest

RWTH Aachen University, Aachen

Johannes Wesling Klinikum Minden, Minden

Policlinico S. Orsola - Malpighi, Bologna

AOU Careggi di Firenze, Florence

AOU Policlinico di Palermo, Palermo

Guy's and St Thomas' NHS Foundation Trust, London

00168

Fondazione Policlinico Universitario A. Gemelli IRCCS UCSC Ematologia, Roma

08034

Hospital Clinic, Hematology Department, Barcelona

All Listed Sponsors
lead

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

OTHER

NCT04192916 - Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms | Biotech Hunter | Biotech Hunter